Research programme - iPSC-CM based cardiovascular therapeutics - Khloris Biosciences
Latest Information Update: 17 Nov 2023
At a glance
- Originator Khloris Biosciences
- Class Cardiovascular therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Arrhythmias; Cardiomyopathies; Heart failure
Most Recent Events
- 16 Oct 2023 Preclinical trials in Arrhythmias in USA (Parenteral) prior to October 2023 (Khloris Biosciences pipeline, October 2023)
- 16 Oct 2023 Preclinical trials in Cardiomyopathies in USA (Parenteral) prior to October 2023 (Khloris Biosciences pipeline, October 2023)
- 16 Oct 2023 Preclinical trials in Heart failure in USA (Parenteral) prior to October 2023 (Khloris Biosciences pipeline, October 2023)